Point-of-care testing program for Hepatitis C screening
Official title: The National Australian HCV Point-of-Care Testing Program: An Observational Cohort Study to Evaluate the Use of Finger-stick Point-of-care Hepatitis C Testing to Enhance Diagnosis and Treatment of HCV Infection - HCV Antibody Testing Minimal Dataset
Run by Kirby Institute · NCT05713136 · Data updated 2026-11-12
This study is testing if quick Hepatitis C tests done during a single visit can help more at-risk adults get diagnosed and start treatment faster.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40000 (estimated) |
| Sponsor | Kirby Institute Government |
| Locations | 13 sites (Canberra, Australian Capital Territory and 12 other locations) |
| Status | Recruiting |
| Started | February 23, 2023 |
| Main results expected | June 2029 |
| Study ends | June 2029 |
| Registry record updated | September 28, 2026 |
| Trial ID | NCT05713136 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this program are adults aged 18 and older who are at risk for Hepatitis C infection.
✕Probably not a fit
Patients who are unable or unwilling to provide informed consent will not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational program aims to evaluate the effectiveness of point-of-care screening tests for Hepatitis C virus exposure in increasing the rates of testing, diagnosis, and treatment among adults at risk. Participants will undergo a finger-prick rapid test for Hepatitis C infection during a single in-person visit. The study will track the proportion of diagnosed individuals who initiate treatment within 12 weeks of diagnosis, providing insights into the impact of immediate testing on patient outcomes.
Why it matters
Potential benefit: If successful, this program could significantly enhance early detection and treatment of Hepatitis C, leading to better health outcomes for patients.
How similar studies have gone: Other studies have shown success with point-of-care testing approaches for infectious diseases, indicating potential for positive outcomes in this program.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provide informed consent * ≥ 18 years of age. Exclusion Criteria: * Is unable or unwilling to provide informed consent
Where it's running
-
Justice Health and Forensic Mental Health Network
Sydney, New South Wales, Australia Recruiting -
West Moreton Hospital and Health Service
Brisbane, Queensland, Australia Recruiting -
Lotus Glen Correctional Centre
Cairns, Queensland, Australia Recruiting -
Woodford Correctional Centre
Woodford, Queensland, Australia Recruiting -
St Vincent's Hospital (Melbourne)
Melbourne, Victoria, Australia Recruiting -
Acacia Prison
Beechina, Western Australia, Australia Recruiting
Show 7 more locations
-
ACT Justice Health
Canberra, Australian Capital Territory, Australia Not yet recruiting -
Queensland Injectors Health Network Ltd
Bowen Hills, Queensland, Australia Active not recruiting -
Townsville Correctional Centre
Townsville, Queensland, Australia Not yet recruiting -
South Australian Prison Health Service
Adelaide, South Australia, Australia Not yet recruiting -
Hepatitis South Australia
Hackney, South Australia, Australia Not yet recruiting -
Tasmanian Prison Service
Hobart, Tasmania, Australia Not yet recruiting -
WA Department of Justice
Perth, Western Australia, Australia Not yet recruiting
Study contacts
- Study coordinator: David Silk, BSc
- Email: dsilk@kirby.unsw.edu.au
- Phone: +61293850900
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Glecaprevir/pibrentasvir started during pregnancy for women with hepatitis C, with or without HIV
This trial will test whether taking glecaprevir/pibrentasvir during pregnancy is safe and how the drug is processed in pregnant women who have hepatitis C, including those who also have HIV, and will follow their infants for 10 weeks after birth.
-
Evaluating hepatitis C treatment during pregnancy
This study tests how well a new hepatitis C treatment works for pregnant adults with a history of drug use and looks at their experience during the treatment.
-
Decentralized treatment for hepatitis C in Brazil
This study is testing a new way to treat hepatitis C in Brazil using a medication called Epclusa to see if it helps more people get the care they need compared to traditional methods.
-
Helping young people who inject drugs start treatment for Hepatitis C
This study tests a new support program to help young adults who inject drugs start treatment for Hepatitis C and see if it works better than regular care.
-
Simplified hepatitis C testing with same-day treatment for people who inject drugs in Armenia, Georgia and Tanzania
This project will test whether a simplified pathway that starts hepatitis C treatment the same day after a quick antibody test helps people who inject drugs in Armenia, Georgia, and Tanzania get treated and cured faster than the usual antibody-plus-RNA pathway.
-
Screening for hepatitis B, hepatitis C and HIV using a dried blood spot
This project will try a simple dried blood spot test to check people who use drugs for hepatitis B, hepatitis C and HIV.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.